Development of acquired @entity447 during treatment of @entity1582 with XXXX .

@entity1 @entity8 @entity417 @entity447 @entity786 @entity797 @entity1582 @entity79 @entity619 @entity1583 @entity6985 @entity1749 @entity617
We describe a 67-year-old female demonstrating symptomatic @entity1582 ( @entity1582 ) with @entity417 and @entity79 initially diagnosed in 2009. Although a partial response was achieved after @entity1749 and @entity619 treatment, @entity1582 recurred in 2012. Therefore, treatment with @entity6985 , @entity786 , and @entity619 was commenced. Coagulation tests conducted prior to the chemotherapy were normal. @entity6985 was discontinued after 10 days due to exacerbation of @entity8 . Simultaneously, activated partial thromboplastin time (APTT) was prolonged to 89.5 seconds. The mixing test showed an inhibitor pattern, with factor @entity797 at 2% and factor @entity797 inhibitor at 4.85 BU/ml. A diagnosis of acquired @entity447 was made, and treatment with @entity617 was started, after which APTT improved to 36.4 seconds and factor @entity797 inhibitor decreased to 1.09 BU/ml. The factor @entity797 inhibitor level again increased concomitantly with restarting @entity6985 , which was, therefore, discontinued, while immunosuppressive therapy was administered with the addition of @entity786 . Factor @entity797 inhibitor gradually disappeared from the @entity1 's blood over the next four months. To the best of our knowledge, this is the first description of @entity6985 as a possible cause of acquired @entity447 . Our experience indicates that we need to pay attention to acquired @entity447 after initiating @entity6985 therapy in @entity1 with @entity1583 .
